Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Lamotrigine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 9/20 | 1.00 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 1.00 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 1.00 |
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamotrigine SCHEMBL29801510 | 1.00 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL35439 | 1.00 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL29360953 | 1.00 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3976546 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL4142403 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3167376 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL1401495 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL17372723 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3976541 | 0.95 | SCN9A (0.91) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL6138267 | 0.91 | SCN9A (0.83) | SCN9ACYP2D6MAOAMAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-3028190-A1 | IDENTIFICATION OF SURGERY CANDIDATES USING NATURAL LANGUAGE PROCESSING | Children's Hospital Medical Center (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2609064-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027693-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-1758600-A4 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MAN SCIENCES LLC (US) | 2008-03-05 | — | — | EP | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1758600-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | Mood Management Sciences, LLC (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005120523-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, LLC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005003104-A3 | CRYSTALLINE FORMS OF LAMOTRIGINE MONOHYDRATE AND ANHYDROUS LAMOTRIGINE AND A PROCESS FOR THEIR PREPARATION | JUBILANT ORGANOSYS LTD (IN) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005003104-A2 | CRYSTALLINE FORMS OF LAMOTRIGINE MONOHYDRATE AND ANHYDROUS LAMOTRIGINE AND A PROCESS FOR THEIR PREPARATION | JUBILANT ORGANOSYS LIMITED (IN) | 2005-01-13 | — | — | WO | disclosed |
| EP-1458692-A1 | A NEW AND EFFICIENT PROCESS FOR THE PREPARATION OF LAMOTRIGINE AND RELATED 3,5-DIAMINO-6-SUBSTITUTED-1,2,4-TRIAZINES | Apotex Pharmachem Inc. (CA) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004045391-A2 | METHODS AND SYSTEMS FOR USING TRANSCRANIAL MAGNETIC STIMULATION AND FUNCTIONAL BRAIN MAPPING FOR EXAMINING CORTICAL SENSITIVITY, BRAIN COMMUNICATION, AND EFFECTS OF MEDICATION | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003078407-A1 | A NEW AND EFFICIENT PROCESS FOR THE PREPARATION OF LAMOTRIGINE AND RELATED 3,5-DIAMINO-6-SUBSTITUTED-1,2,4-TRIAZINES | APOTEX PHARMACHEM INC. (CA) | 2003-09-25 | — | — | WO | disclosed |
| US-6586593-B1 | Reacting 2,3-dichlorobenzoyl cyanide with aminoguanidine salts in the presence of acids, then dehydrating and cylcization of the chemical intermeadiate to form antiepileptic agents | BRANTFORD CHEMICALS INC. (CA) | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | SLC6A4, SLC1A2, SLC6A2 | SCN9A 680/4885SCN4A 625/4885SCN5A 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.